Markets:

Overview

News

Currencies

International

Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

14.22 -0.59 (-3.98%)

Streaming Delayed Price Updated: 10:02 AM EDT, Sep 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 ↗

Today 7:02 EDT

Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978...

Via MarketBeat

Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones ↗

August 06, 2026

Via Chartmill

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

June 08, 2026

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell...

Via Benzinga

Topics Stocks

Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts ↗

May 07, 2026

Via Chartmill

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus ↗

November 06, 2025

Cullinan Therapeutics (CGEM) beat Q3 2025 EPS estimates, announced a strategic pipeline focus, and has cash into 2029.

Via Chartmill

Topics Earnings

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations ↗

October 13, 2025

Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.

Via Benzinga

Cullinan (CGEM) Q2 R&D Jumps 68% ↗

August 07, 2025

Via The Motley Fool

CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs ↗

August 07, 2025

Cullinan Therapeutics (CGEM) reported a Q2 2025 net loss of $70.1M (-$1.07/share), missing EPS estimates. Revenue was $0.0. R&D costs rose, but cash reserves remain strong at $510.9M. Stock dipped 2.7%...

Via Chartmill

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix ↗

June 05, 2025

Cullinan Therapeutics secured global rights, excluding Greater China, to velinotamig from Genrix Bio, expanding its autoimmune pipeline with a second T cell engager.

Via Stocktwits

Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

April 21, 2025

Via Benzinga

Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 15, 2025

Via Benzinga

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 26, 2024

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.

Via Benzinga

Topics Stocks

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst ↗

August 09, 2024

Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and...

Via Benzinga

CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024 ↗

August 08, 2024

CGEM stock results show that Cullinan Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 ↗

May 15, 2024

CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 29, 2024

Via Benzinga

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday ↗

April 29, 2024

Via Benzinga

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 26, 2024

Via Benzinga

Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday ↗

April 26, 2024

Via Benzinga

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? ↗

April 24, 2024

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.